SCHEMBL2380452

SCHEMBL2380452

CC1(C)c2ccccc2-c2ccc(-c3c4ccccc4c(Br)c4cc5c(cc34)C(C)(C)c3ccccc3-5)cc21

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 7/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082867 0.93 PDK2 (0.35) PDK2
SCHEMBL12560709 0.92 PDK2 (0.34) PDK2
SCHEMBL12560686 0.92 PDK2 (0.34) PDK2
SCHEMBL4234951 0.92 PDK2 (0.35) PDK2
SCHEMBL2381039 0.91 PDK2 (0.33) PDK2
SCHEMBL2381089 0.91 KDM4E (0.31)
SCHEMBL19564781 0.91
SCHEMBL2379615 0.90 HDAC4 (0.33)
SCHEMBL2378738 0.90 PDK2 (0.40) PDK2
SCHEMBL2379606 0.89 PDK2 (0.32) PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8525158-B2 Anthracene derivative and organic electroluminescence element using the same DOOSAN CORPORATION (KR) 2013-09-03 US disclosed
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME DOOSAN CORPORATION (KR) 2011-09-01 US disclosed
WO-2010027181-A2 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME 주식회사 두산 (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME KCNJ2, KCNJ1, BRD4 PDK2 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.